Turning Complex Radiochemistry Into Clinical Reality

The programme will be overseen by Dr Louis Allott, a member of Aptamer's Scientific Advisory Board and a recognised expert in the development and production of radiopharmaceuticals, with direct experience spanning laboratory discovery through to clinical translation.

Through his consultancy, Radiopharmium Ltd, Dr Allott will take a fractional role as Director of Radioligand Development for Aptamer, overseeing the radiochemical conjugation of Optimer® binders and their biological evaluation in established preclinical models. This work will involve the design, synthesis, and evaluation of radiolabelled Optimer®‑based ligands in validated animal models to assess safety, targeting performance, and therapeutic potential prior to clinical trials.

Dr Arron Tolley, Chief Executive Officer of Aptamer Group, commented: "We are excited to launch this programme in a high‑growth field where the limitations of existing targeting technologies create a compelling opportunity for our Optimer® platform.

A key challenge in radiopharmaceuticals is maintaining the stability of the targeting molecule once it is carrying a radioactive payload. Our data indicates that Optimer®-based radioligands may offer improved stability compared to existing approaches, which could translate into practical advantages in manufacturing, distribution, and clinical use, subject to further validation.

With Louis leading this programme and access to world-class preclinical models through Radiopharmium, we are well-positioned to advance multiple assets towards in vivo validation and further demonstrate the potential of our platform in this rapidly growing therapeutic field."

Dr Louis Allott, Chief Executive Officer of Radiopharmium Ltd, commented: "I am delighted to be working with Aptamer, a recognised leader in the field of aptamer technology with a strong track record of success. The combination of Aptamer's innovative Optimer® platform and Radiopharmium's expertise in radiopharmaceutical development makes this collaboration well‑positioned to demonstrate the potential of aptamer‑based targeting in next‑generation radiopharmaceuticals."